Back to today’s briefing

Story perspectives

uniQure's Gene Therapy May Slow Huntington's Progression by 75%

9/29/2025

43 8

Summary

Story summary

uniQure's Huntington's gene therapy shows potential to slow progression by 75% in preliminary results.
Delivered during brain surgery, it could improve quality of life but does not cure.
Trial size is about 30 patients and data have not yet been peer reviewed.
Food and Drug Administration (FDA) meeting planned in 2026; families hopeful, but costs around $2 million raise concerns.

1 of 1

Story summary

uniQure's Huntington's gene therapy shows potential to slow progression by 75% in preliminary results.
Delivered during brain surgery, it could improve quality of life but does not cure.
Trial size is about 30 patients and data have not yet been peer reviewed.
Food and Drug Administration (FDA) meeting planned in 2026; families hopeful, but costs around $2 million raise concerns.